Home › Trials › NCT06112743

Evaluating the effects of Mavacamten on heart structure in patients with obstructive hypertrophic cardiomyopathy

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)

Phase 4 Interventional Bristol-Myers Squibb · NCT06112743

This study is testing if a medication called Mavacamten can improve heart structure in adults with obstructive hypertrophic cardiomyopathy.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment85 (estimated)
Ages18 Years and up
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Locations89 sites (Los Angeles, California and 88 other locations)
Trial IDNCT06112743 on ClinicalTrials.gov

What this trial studies

This study aims to assess the impact of Mavacamten on myocardial structure in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Participants will undergo cardiac magnetic resonance imaging (CMR) to evaluate changes in heart structure. Eligible candidates must have specific functional class symptoms and measurable cardiac parameters as defined by established guidelines. The study is interventional and is classified as Phase 4.

Who should consider this trial

Good fit: Ideal candidates are adults with symptomatic obstructive hypertrophic cardiomyopathy who meet specific cardiac function criteria.

Not a fit: Patients with other cardiac conditions that mimic obstructive hypertrophic cardiomyopathy or those with significant coronary artery disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with obstructive hypertrophic cardiomyopathy.

How similar studies have performed: Previous studies have shown promise in using Mavacamten for treating obstructive hypertrophic cardiomyopathy, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:.
* Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
* Left ventricular ejection fraction (LVEF) ≥ 55% at rest.
* New York Heart Association (NYHA) functional class II or III symptoms.

Exclusion Criteria

* A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM.
* Documented obstructive coronary artery disease or history of myocardial infarction.
* A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening.
* An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR).
* Other protocol-defined inclusion/exclusion criteria apply.

Where this trial is running

Los Angeles, California and 88 other locations

+39 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Cardiomyopathy, HypertrophicBMS-986427MYK-461MavacamtenObstructive Hypertrophic CardiomyopathyCamyzosCardiac Magnetic Resonance Imaging
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.